Commenting on the results of the study, Dr. Joan Schiller, Professor of Oncology at the University of Wisconsin, and lead investigator for the trial, noted, The results from this first clinical trial indicate squalamine shows promise as a novel therapy for patients with this devastating disease. I look forward to participating in the further development of squalamine for the treatment of lung cancer. Dr. Kenneth Holroyd, Senior Vice President of Clinical Research and Regulatory Affairs commented, This successful trial enabled us to establish clinical activity for squalamine in lung cancer. I look forward to working with our outstanding scientific and medical collaborators in further developing squalamine for lung cancer, and a number of other important medical conditions. Magainin also outlined further clinical development plans for squalamine.
Clinical studies are also underway in both primary and recurrent ovarian cancer.
The Company expects to focus its efforts going forward in recurrent and resistant disease patients, where the Company has seen encouraging early objective responses. Michael R. Dougherty, President and Chief Executive Officer commented, We are delighted with the activity of squalamine demonstrated in this phase 2 study. Achieving our objectives in this trial is an important step forward for our company, and for our aminosterol platform of proprietary compounds. The clinical program for squalamine expands, and there are multiple opportunities for success with this unique anti-angiogenic agent. Our leadership in leveraging the value of natural product discovery and genomics into promising new drugs has made possible the development of novel therapies such as squalamine.